Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,232,005 papers from all fields of science
Search
Sign In
Create Free Account
incobotulinumtoxinA
Known as:
BoNT-A
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Broader (3)
Botulinum Toxin Type A
Neuromuscular Agents
Neurotoxins
INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT
Narrower (3)
NT 201
Xeomin
bocouture
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea
W. Jost
,
A. Friedman
,
+10 authors
A. Blitzer
Neurology
2019
Corpus ID: 85545657
Objective This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of…
Expand
Highly Cited
2017
Highly Cited
2017
Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity
J. Wissel
,
D. Bensmail
,
+11 authors
D. Simpson
Neurology
2017
Corpus ID: 18195383
Objective: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA…
Expand
2017
2017
Botulinum Toxin in Parkinson Disease Tremor: A Randomized, Double-Blind, Placebo-Controlled Study With a Customized Injection Approach.
S. Mittal
,
Duarte G. Machado
,
D. Richardson
,
D. Dubey
,
B. Jabbari
Mayo Clinic proceedings
2017
Corpus ID: 24349264
Highly Cited
2016
Highly Cited
2016
Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity
E. Elovic
,
M. Munin
,
P. Kaňovský
,
A. Hanschmann
,
R. Hiersemenzel
,
C. Marciniak
Muscle & nerve
2016
Corpus ID: 16072341
Introduction: Efficacy and safety of incobotulinumtoxinA in post‐stroke upper‐limb spasticity were studied. Methods: Subjects…
Expand
2013
2013
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm
D. Truong
,
S. Gollomp
,
+4 authors
H. Fernandez
Journal of Neural Transmission
2013
Corpus ID: 17353081
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous…
Expand
2013
2013
A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia
V. Evidente
,
H. Fernandez
,
+4 authors
C. Comella
Journal of Neural Transmission
2013
Corpus ID: 8428934
IncobotulinumtoxinA (Xeomin®, NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and…
Expand
Highly Cited
2011
Highly Cited
2011
Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay
D. Dressler
,
Gerd J. Mander
,
K. Fink
Journal of Neural Transmission
2011
Corpus ID: 6522259
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling…
Expand
Highly Cited
2011
Highly Cited
2011
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia
C. Comella
,
J. Jankovic
,
D. Truong
,
A. Hanschmann
,
S. Grafe
Journal of the Neurological Sciences
2011
Corpus ID: 5068690
2011
2011
A Phase III Study of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines.
M. Imhof
,
U. Kühne
The Journal of clinical and aesthetic dermatology
2011
Corpus ID: 43319090
OBJECTIVE To investigate the efficacy and safety of incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free…
Expand
Highly Cited
2010
Highly Cited
2010
Noninferiority of IncobotulinumtoxinA, Free from Complexing Proteins, Compared with Another Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
G. Sattler
,
M. Callander
,
+5 authors
A. Carruthers
Dermatologic surgery : official publication for…
2010
Corpus ID: 24823075
BACKGROUND Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE